Simulations Plus (NASDAQ:SLP) Releases FY24 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.54-0.56 for the period, compared to the consensus estimate of $0.55. The company issued revenue guidance of $69-72 million, compared to the consensus revenue estimate of $70.87 million.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SLP. Oppenheimer increased their price target on Simulations Plus from $55.00 to $65.00 and gave the stock an outperform rating in a research report on Thursday, June 13th. Craig Hallum raised their price objective on Simulations Plus from $51.00 to $56.00 and gave the company a buy rating in a report on Thursday, June 13th. Finally, William Blair began coverage on Simulations Plus in a report on Friday. They set an outperform rating on the stock.

Simulations Plus Trading Up 1.5 %

NASDAQ:SLP traded up $0.68 during trading hours on Tuesday, hitting $46.86. 261,871 shares of the company were exchanged, compared to its average volume of 102,801. The stock has a market capitalization of $936.73 million, a price-to-earnings ratio of 86.58 and a beta of 0.72. Simulations Plus has a one year low of $32.69 and a one year high of $52.69. The company has a fifty day simple moving average of $47.80 and a 200 day simple moving average of $44.14.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Wednesday, April 3rd. The technology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.02. The business had revenue of $18.31 million during the quarter, compared to analyst estimates of $17.31 million. Simulations Plus had a return on equity of 7.95% and a net margin of 16.22%. Simulations Plus’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same period last year, the company earned $0.20 EPS. Equities research analysts predict that Simulations Plus will post 0.55 earnings per share for the current fiscal year.

Simulations Plus Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 6th. Stockholders of record on Monday, April 29th were given a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 0.51%. The ex-dividend date was Friday, April 26th. Simulations Plus’s dividend payout ratio (DPR) is presently 45.28%.

Insider Transactions at Simulations Plus

In other news, Director Daniel L. Weiner sold 3,250 shares of Simulations Plus stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total value of $157,007.50. Following the completion of the transaction, the director now directly owns 8,759 shares of the company’s stock, valued at approximately $423,147.29. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Daniel L. Weiner sold 3,250 shares of Simulations Plus stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total value of $157,007.50. Following the completion of the transaction, the director now directly owns 8,759 shares of the company’s stock, valued at approximately $423,147.29. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel L. Weiner sold 750 shares of Simulations Plus stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $49.32, for a total value of $36,990.00. Following the completion of the transaction, the director now directly owns 7,009 shares of the company’s stock, valued at $345,683.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,500 shares of company stock valued at $2,072,198. Corporate insiders own 20.90% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.